echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bayer withdraws PI3K inhibitor application for one indication

    Bayer withdraws PI3K inhibitor application for one indication

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 21, the State Food and Drug Administration announced the pending receipt of the drug notification, and Bayer's PI3K inhibitor copanlisib was listed


    Copanlisib is an intravenously administered phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity against both PI3K-α and PI3K-δ isoforms expressed in malignant B cells, which can be inhibited by apoptosis apoptosis and inhibit the proliferation of malignant B cells to induce tumor cell death


    Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.


    According to the European Medicines Agency (EMA) website, Bayer withdrew a marketing application for copanlisib in the EU in December 2021 for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.